Agilent Cytation 9 Cell Imaging Multimode Reader, or equivalent instrument

The Food and Drug Administration is conducting market research to identify sources for an Agilent Cytation 9 Cell Imaging Multimode Reader or an equivalent instrument. This notice establishes the technical baseline and mandatory qualifications for a future solicitation, focusing on hardware capabilities and software integration for laboratory imaging. The scope includes delivery and installation of equipment that meets specific performance requirements for imaging and plate reading. A central requirement is the trade-in of a legacy Agilent BioTek Cytation 3 system. The agency is seeking capability statements that address minimum performance requirements and salient characteristics. The notice also identifies a 43.1% manufacturer-backed credit requirement that must be verified through the supply chain as part of the qualification process. The FDA is identifying sources for an Agilent Cytation 9 Cell Imaging Multimode Reader or equivalent to establish technical baselines for a future solicitation. The FDA National Center for Toxicological Research (NCTR) requires an Agilent Cytation 9 Cell Imaging Multimode Reader or equivalent to modernize genotoxicity data collection. The system will support high-content imaging and multimode detection for 3D spheroids, organoids, and other cell culture models.